Postdoctoral Researchers (MIT)

• Dr. Alessandro Angelini, 2012-2016. Ca’ Foscari University of Venice, Italy, Department of Molecular Sciences and Nanosystems.
• Dr. Michael Traxlmayr, 2013-2015. University of Natural Resources and Life Sciences, Vienna, Austria.
• Dr. James Van Deventer, 2011-2015. Tufts University, Dept. of Chemical and Biological Engineering
• Dr. Pankaj Karande, 2006-2007. Rensselaer Polytechnic Institute, Dept. of Chemical and Biological Engineering
• Dr. Wai Lau, 2004-2007. Bristol-Myers Squibb Adnexus Therapeutics, Waltham, MA
• Dr. Letha Sooter, 2005-2006. West Virginia University
• Dr. Dasa Lipovsek, 2003-2006. Bristol-Myers Squibb Adnexus Therapeutics, Waltham, MA
• Dr. Andrea Piatesi, 2004-2006. BASF, Germany
• Dr. Yong-Sung Kim, 2002-2004. Ajou University, Seoul, Korea
• Dr. Mark J. Olsen, 2002-2004. West Texas A&M University, Dept. of Biochemistry
• Dr. Jennifer R. Cochran, 2002-2004. Stanford University, Dept. of Bioengineering
• Dr. Brenda A. Kellogg, 2000-2002. Bluestream Laboratories

Graduate Students (MIT Ph.D)

• Adrienne Rothschilds. “Engineering protein-based modulators of allergic, temporal, and checkpoint blockade anti-cancer immunity”, 2019. Flagship Pioneering, Cambridge, MA
• Naveen Mehta. “Engineering more potent vaccines for the treatment of cancer and autoimmunity”, 2019. Cullinan Oncology, Cambridge, MA
• Alison Tisdale. “Engineering new approaches for potentiating and studying EGFR-targeted therapies”, 2019. Flagship Pioneering VL56, Cambridge, MA
• Monique Kauke. “Targeting Immunosuppression in the Tumor Microenvironment and Protein-based Antagonism of Oncogenic K-Ras”, 2017. Codiak BioSciences, Cambridge, MA
• Ryan Kelly. “Determinants of Antibody Specificity”, 2017. xCella Biosciences, Menlo Park, CA.
• Eric Zhu. “Synergistic Anti-Tumor Immune Response to Combination Immunotherapy Consisting of Anti-Tumor Antibodies, Extended Half-Life Interleukin-2, and Other Immunomodulatory Agents”, 2016. Cygnal Therapeutics, Cambridge, MA.
• Alice Tzeng. “Improving methods for cytokine immunotherapy of cancer “, 2016. Cleveland Clinic, Cleveland, OH
• Byron Kwan. “Integrin-targeted Cancer Immunotherapy”, 2016. Seattle Genetics, Bothell, WA.
• Katie Maass, “Quantitative Analysis of Cellular Processing of Antibody-Drug Conjugates”, 2015. Genentech, South San Francisco, CA.
• Nicole Yang, “Reversibly Neutralized Perfringolysin O for Intracellular Delivery of Macromolecules”, 2015. Chiu Lab, Harvard Medical School.
• Cary Opel, “T Cell Mediated Combination Immunotherapy”, 2015. Gilead, Oceanside, CA.
• Seymour de Picciotto, “Protein Engineering Design Principles for the Development of Biosensors”, 2015. Moderna, Cambridge, MA.
• Tiffany Chen, “Engineering Therapeutic Proteins for Immune Modulation”, 2014. Rubius Therapeutics, Cambridge, MA.
• Xiaosai Yao, “Functional Characterization of Mobilized Tumor Cells”, 2013. A*Star National Science Scholar, Singapore, Singapore
• Jordi Mata-Fink, “Engineering of HIV gp120 by Yeast Surface Display for Neutralizing Antibody Characterization and Immunogen Design”, 2012. Flagship Ventures, Cambridge, MA
• John Rhoden, “Quantitative analysis of perivascular antibody distribution in solid tumors”, 2012. Eli Lilly and Company, Indianapolis, IN
• Shuning (Annie) Gai , “Engineering Persistent Interleukin-2 for Cancer Immunotherapy”, 2012. Hubbell Lab, EPFL.
• David V. Liu , “Protein Engineering for Cancer Therapy”, 2011. Stem CentRx, South San Francisco, CA
• Christopher Pirie , “Engineering Targeted Proteins for Intracellular Delivery of Biotherapeutics “, 2011. Manus Biosynthesis, Cambridge, MA
• Jamie Spangler, “Characterization and informed design of downregulating anti-epidermal growth factor receptor antibodies”, 2011. Spangler Lab, John Hopkins University.
• Michael Schmidt, “Engineering Antibodies for Improved Targeting of Solid Tumors”, 2009. Compass Therapeutics, Cambridge, MA
• Kelly Davis Orcutt, “Protein Engineering for Targeted Delivery of Radionuclides toTumors”, 2009. inviCRO, Boston, MA
• Eileen Higham, “Overcoming Dendritic Cell-Mediated Suppression of T Cell Responses in a Prostate Tumor Environment”, 2009. MedImmune
• Margaret Ackerman , “Targeting the Tight Junction: Immunotherapy of Colon Cancer “, 2009. Assistant Professor, Thayer School of Engineering, Dartmouth College
• Ben Hackel, “High affinity Fn3 engineering”, 2009. Assistant Professor, Chemical Engineering and Materials Science, University of Minnesota.
• Stephen Sazinsky, “Aglycosylated IgGs with enhanced immune effector function”, 2008. Merrimack Pharmaceuticals, Cambridge, MA
• Shanshan Howland, “Yeast based cancer vaccines,” 2008. Renia Lab, Singapore Immunology Network, Singapore, Singapore
• Greg Thurber, “Tumor targeting with antibodies,” 2008. Assistant Professor, Chemical Engineering, University of Michigan.
• Ginger Chao, “Anti-EGFR antibody engineering,” 2007. Bristol-Myers Squibb Adnexus Therapeutics, Waltham, MA
• Shaun M. Lippow, “Computational analysis, design, and experimental validation of antibody binding affinity improvements beyond in vivo maturation,” 2007. Silver Creek Pharmaceuticals, San Francisco, CA
• Stefan Zajic, “Improved methods and reagents for pretargeted radioimmunotherapy of cancer,” 2006. Merck
• J. Andrew Rakestraw, “A directed evolution approach to engineering recombinant protein production in S. cerevisiae,” 2006. Celexion LLC , Cambridge, MA
• David W. Colby, “Isolation, engineering, and characterization of intracellular antibodies specific for the huntingtin protein,” 2005. University of Delware
• Y. Andrew Yeung, 2005. Pfizer Rinat, San Francisco, CA
• Jeffrey S. Swers, “Isolation and engineering of a high affinity antibody against P-selectin glycoprotein Ligand-1 (PSGL-1),” 2005. MedImmune, Inc.
• Balaji M. Rao, 2004. Assistant Professor Dept. of Chemical Engineering, North Carolina State University
• Katarina Midelfort, “Biophysical characterization of high affinity engineered single chain Fv antibody fragments,” 2004. Milwaukee School of Engineering
• Christilyn P. Graff, “Antibody Engineering for Tumor Immunotherapy,” 2002. Biogen Idec, Cambridge, MA

Postdoctoral Researchers (University of Illinois)

• Dr. Won Shik Kwon, 1997-1998.

Graduate Students (University of Illinois Ph.D)

• Bannister, Sarah, “Increasing Heterologous Protein Secretion from the Yeast S. cerevisiae Through Manipulation of Cellular Redox Factors,” 2000. Associate Director, Alternative and Public Interest Careers, University of Oregon School of Law.
• VanAntwerp, Jennifer, “Affinity Maturation of the D1.3 Antibody Using Yeast Surface Display and Flow Cytometry,” 1999. Calvin College
• Shusta, Eric, “The Production of Recombinant Immunoglobulin Superfamily Proteins in the Yeast Saccharomyces cerevisiae,” 1999. University of Wisconsin at Madison
• Boder, Eric, “Molecular Engineering of a Single Chain Fv Antibody Fragment to Femtomolar Affinity,” 1999. University of Tennessee – Knoxville.
• Kowalski, Jean, “The Effect of Stability and Surface Charge Distribution on Secretion of Bovine Pancreatic Trypsin Inhibitor from Yeast,” 1998. McKinsey & Co
• Parekh, Rajesh, “Disulfide Formation Kinetics of a Model Protein (BPTI) in Yeast,” 1996. Leader of McKinsey’s Asia Pharmaceuticals and Medical Products Practice, McKinsey & Co.
• Shaw, Mark, “Gene Amplification for the Improved Secretion of Foreign Proteins in the Yeast Saccharomyces cerevisiae,” 1995. Senior R&D Manager, Beckman Coulter.
• Farrell nee Arnold, Caron, “Targeting and Translocation Mechanisms in the Secretory Pathway of the Yeast Saccharomyces cerevisiae,” 1995. Child Psychiatry, Austin, TX
• Robinson, Anne, “The Role of BiP and PDI in Foreign Protein Secretion in Yeast,” 1994. (co-advised with Prof. Douglas Lauffenburger) Tulane University.